Biotechnology Industry
Filter News
Found 14,140 articles
-
Luna Design and Innovation selected as a Channel Partner for Blue Origin
7/23/2019
Luna Design and Innovation Inc., a Toronto-based biotechnology company, announced that it has been selected as an Official Channel Partner for Blue Origin’s New Shepard reusable suborbital rocket system.
-
Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call
7/23/2019
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the second quarter 2019 on Tuesday, August 6 at 4:30 p.m. ET / 1:30 p.m. PT
-
X-Vax Technology Raises $56 Million in Upsized Series A Financing to Advance Lead Herpes Vaccine Program
7/23/2019
X-Vax Technology, Inc. (X-VAX ™), a biotechnology company developing vaccines based on a new approach that mediates the killing of infected cells, today announced that it has raised $56 million in an upsized Series A financing with participation from strategic and institutional investors, including Johnson & Johnson Innovation
-
Frequency Therapeutics Completes $62 Million Series C Financing
7/23/2019
Frequency Therapeutics announced the closing of a $62.0 million Series C financing.
-
Advaxis, Inc. Announces Pricing of $16 Million Public Offering
7/23/2019
Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of (i) 9,200,000
-
LifeSpan BioSciences Releases Best-In-Class PathPlus™ Top Performing Immunohistochemistry Antibodies for Cancer Targets
7/23/2019
LifeSpan BioSciences, Inc., the industry leader in molecular pathology, announced the first release of its PathPlus™ series of antibodies.
-
Gain Therapeutics SA Announces Award Notification of a €1.4M Grant Support From Eurostars-2 Together With the Institute for Research in Biomedicine and Neuro-Sys SAS After Having Scored 2nd Among 325 Eligible Applications
7/23/2019
Gain Therapeutics SA announced that together with Dr. Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona (Switzerland) affiliated to the Università della Svizzera italiana (USI) and Neuro-Sys SAS in Gardanne (France), it has received funding support from Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency.
-
University of Puerto Rico Joins Caris Life Sciences' Precision Oncology Alliance
7/23/2019
Puerto Rico's primary healthcare and medical research institution becomes the 28th member of Caris' collaborative network dedicated to making cancer treatment more precise and effective.
-
Stero Biotechs to Commence Phase 2a Clinical Trial of Cannabidiol-Based Formulation for Patients With Crohn's Disease
7/23/2019
Stero Biotechs, an Israel-based, clinical-stage company focused on Cannabidiol formulation research and development, received its second Helsinki approval to move forward with a second Phase 2a clinical trial.
-
“We are pleased to be working on this program with Gilead given their expertise and global leadership in the HIV and HBV fields,” stated James E. Brown, president and chief executive officer of DURECT.
-
For John Cumbers, chief executive officer of SynBioBeta, turning rural America into a biotech hotbed may be an answer to kick start the local economies and advance new products that could benefit the nation and world.
-
Clinical Catch-up for July 15-19
7/22/2019
Here's a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more. -
The FDA approval marks the first for oral ulcers associated with Behçet’s Disease and the third for Otezla.
-
Achillion’s ACH-5228 Achieves Positive Results In Phase 1 Multiple Ascending Dose Study In Healthy Volunteers
7/22/2019
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, announced results from their Phase 1 multiple ascending dose study with ACH-5228 outside of the United States.
-
NUMAFERM closes licensing agreement with PEPDesign
7/22/2019
Low cost production and superior product purity of the diabetes drug liraglutide with NUMAFERM's unique technology platform
-
Exicure Appoints Jeffrey L. Cleland and Tim Walbert to Board of Directors
7/22/2019
Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced its appointment of Jeffrey L. Cleland, Ph.D. and Timothy P. Walbert to its Board of Directors.
-
Spectrum Announces Expansion of the Poziotinib Clinical Program
7/22/2019
Spectrum Pharmaceuticals, Inc., announced that it is further expanding its poziotinib clinical program by adding three new cohorts in its cornerstone poziotinib clinical trial, ZENITH20.
-
Resolve Therapeutics Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus
7/22/2019
Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, announced completion of enrollment in its Phase 2a study of RSLV-132 for the treatment of Systemic Lupus Erythematosus (SLE; “lupus”).
-
Company Profile for Delaware BioScience Association
7/22/2019
Formed in early 2006, Delaware BioScience Association (Delaware Bio) has brought together pharmaceutical and biotechnology firms, medical device manufacturers, agricultural biotech and chemical companies, research and testing companies, hospitals and medical institutions, and other organizations and related service companies, with the shared goal of expanding our state’s vibrant science economy
-
Tiziana Reports Phase 2a Clinical Data with Milciclib Monotherapy in Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma
7/22/2019
Tiziana Life Sciences plc announced preliminary topline clinical data from a Phase 2a trial of Milciclib as a monotherapy in patients with advanced hepatocellular carcinoma, the most common form of liver cancer.